Structure Therapeutics Earnings Reports

Structure Therapeutics Inc. reported a net loss of $46.833 million for the three months ended March 31, 2025, compared to a net loss of $26.036 million for the same period in 2024. This increased loss was primarily due to a significant rise in research and development expenses, which more than doubled year-over-year, and an increase in general and administrative costs. The company's cash and cash equivalents, along with short-term investments, totaled $836.9 million as of March 31, 2025, which management believes is sufficient to fund operations through at least 2027.

Structure Therapeutics reported a net loss of $36.479 million for the fourth quarter of 2024, compared to a net loss of $24.503 million in the same period last year. The company's cash, cash equivalents, and short-term investments totaled $883.518 million at year-end 2024, indicating a strong financial position.

Structure Therapeutics reported a net loss of $34.0 million for the third quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $915.3 million as of September 30, 2024, which is expected to fund operations through at least 2027.

Structure Therapeutics reported its second quarter 2024 financial results, highlighting a strong cash position of $927.1 million, which is expected to fund operations through at least 2027. The company is advancing its GSBR-1290 program with a Phase 2b study expected to start in Q4 2024 and anticipates selecting a development candidate for its amylin program in the same quarter.

Structure Therapeutics reported a net loss of $26.0 million for the first quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $436.4 million as of March 31, 2024, which is expected to fund operations through at least 2026.

Structure Therapeutics reported its Q4 2023 financial results, highlighting a cash balance of $467.3 million, which is expected to fund operations through 2026. The company's R&D expenses were $20.0 million for the quarter, and G&A expenses were $11.0 million. The net loss for the quarter totaled $24.5 million.